Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis

BMC Genetics

Nengneng Zheng²  Jiezuan Yang³  Ying Zheng²  Renyong Guo¹ 

[1] Department of Laboratory Medicine, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China;Department of Gynecology and Obstetrics, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, China;State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China

关键词: Meta-analysis;    Polymorphism;    IL-1beta;    IL-6;    TNF-alpha;    Polycystic ovary syndrome;   

Others  :  1121332
DOI  :  10.1186/s12863-015-0165-4

 received in 2014-10-12, accepted in 2015-01-16,  发布年份 2015

【 摘 要 】

Background

Several studies on the association of TNF-alpha (−308 G/A), IL-6 (−174 G/C) and IL-1beta (−511 C/T) polymorphisms with polycystic ovary syndrome (PCOS) risk have reported conflicting results. The aim of the present study was to assess these associations by meta-analysis.

Results

A total of 14 eligible articles (1665 cases/1687 controls) were included in this meta-analysis. The results suggested that there was no obvious association between the TNF-alpha (−308 G/A) polymorphism and PCOS in the overall population or subgroup analysis by ethnicity, Hardy–Weinberg equilibrium (HWE) in controls, genotyping method, PCOS diagnosis criteria, and study sample size. Also, no obvious association was found between the TNF-alpha (−308 G/A) polymorphism and obesity in patients with PCOS (body mass index [BMI] ≥ 25 kg/m² vs. BMI < 25 kg/m²). Regarding the IL-6 (−174 G/C) polymorphism, also no association was found in the overall population in heterozygote comparison, dominant model, and recessive model. Even though an allelic model (odds ratio [OR] = 0.63, 95% confidence interval [CI] = 0.41–0.96) and a homozygote comparison (OR = 0.52, 95% CI = 0.30–0.93) showed that the IL-6 (−174 G/C) polymorphism was marginally associated with PCOS. Further subgroup analysis suggested that the effect size was not significant among HWE in controls (sample size ≤ 200) and genotyping method of pyrosequencing under all genetic models. Similarly, there was no association between the IL-1beta (−511 C/T) polymorphism and PCOS in the overall population or subgroup analysis under all genetic models. Furthermore, no significant association was found between the IL-1beta (−511 C/T) polymorphism and several clinical and biochemical parameters in patients with PCOS.

Conclusions

The results of this meta-analysis suggest that the TNF-alpha (−308 G/A), IL-6 (−174 G/C), and IL-1beta (−511 C/T) polymorphisms may not be associated with PCOS risk. However, further case–control studies with larger sample sizes are needed to confirm our results.

【 授权许可】

   
2015 Guo et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745-2749.
• [2]Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R: Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011, 7:219-231.
• [3]Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, et al.: Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 2006, 5:17-34.
• [4]Deligeoroglou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifakis S, Iliodromiti S, et al.: Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol 2012, 28:974-978.
• [5]Escobar-Morreale HF, Calvo RM, Sancho J, San Millan JL: TNF-alpha and hyperandrogenism: a clinical, biochemical, and molecular genetic study. J Clin Endocrinol Metab 2001, 86:3761-3767.
• [6]Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, et al.: Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006, 55:1076-1082.
• [7]Xia YH, Yao L, Zhang ZX: Correlation between IL-1β, IL-1Ra gene polymorphism and occurrence of polycystic ovary syndrome infertility. Asian Pac J Trop Med 2013, 6:232-236.
• [8]Brannstrom M, Friden BE, Jasper M, Norman RJ: Variations in peripheral blood levels of immunoreactive tumor necrosis factor alpha (TNFalpha) throughout the menstrual cycle and secretion of TNFalpha from the human corpus luteum. Eur J Obstet Gynecol Reprod Biol 1999, 83:213-217.
• [9]Deshpande RR, Chang MY, Chapman JC, Michael SD: Alteration of cytokine production in follicular cystic ovaries induced in mice by neonatal estradiol injection. Am J Reprod Immunol 2000, 44:80-88.
• [10]Sukhikh GT, Vanko LV: Interrelationships between Immune and Reproductive Systems in Human. Russ J Immunol 1999, 4:312-314.
• [11]Baghel K, Srivastava RN, Chandra A, Goel SK, Agrawal J, Kazmi HR, et al.: TNF-alpha, IL-6, and IL-8 cytokines and their association with TNF-alpha-308 G/A polymorphism and postoperative sepsis. J Gastrointest Surg 2014, 18:1486-1494.
• [12]Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al.: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376.
• [13]Dundar NO, Aktekin B, Ekinci NC, Sahinturk D, Yavuzer U, Yegin O, et al.: Interleukin-1beta secretion in hippocampal sclerosis patients with mesial temporal lobe epilepsy. Neurol Int 2013, 5:e17.
• [14]Milner CR, Craig JE, Hussey ND, Norman RJ: No association between the −308 polymorphism in the tumour necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries. Mol Hum Reprod 1999, 5:5-9.
• [15]Mao WW, Yu L, Chen YJ, Zhang XW, Li MZ: Study on the relationship between a polymorphism of tumor necrosis factor-α gene and the pathogenesis of polycystic ovary syndrome. Chin J Obstet Gynecol 2000, 2000:536-539.
• [16]Zhang J, Liu Q: Association study of genetic polymorphisms in LEP and TNFα genes with the pathogenesis of polycystic ovary syndrome. Chin J Heath Lab Technol 2010, 20:3272-3274.
• [17]Deepika ML, Reddy KR, Yashwanth A, Rani VU, Latha KP, Jahan P: TNF-alpha haplotype association with polycystic ovary syndrome - a South Indian study. J Assist Reprod Genet 2013, 30:1493-1503.
• [18]Wen Q, Wu J, Wu LY, Liu LJ, Yang HB, Sun ZX, et al.: Association of TNF-α G-308A and G-238A gene polymorphisms with PCOS in women. Chin J Clin 2013, 7:3394-3399.
• [19]Grech I, Giatrakos S, Damoraki G, Kaldrimidis P, Rigopoulos D, Giamarellos-Bourboulis EJ: Impact of TNF haplotypes in the physical course of acne vulgaris. Dermatology 2014, 228:152-157.
• [20]Walch K, Grimm C, Zeillinger R, Huber JC, Nagele F, Hefler LA: A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril 2004, 81:1638-1641.
• [21]Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Yilmaz C: The relationship of the interleukin-6–174 G > C gene polymorphism with cardiovascular risk factors in Turkish polycystic ovary syndrome patients. Int J Immunogenet 2009, 36:283-288.
• [22]Vural P, Degirmencioglu S, Saral NY, Akgul C: Tumor necrosis factor alpha (−308), interleukin-6 (−174) and interleukin-10 (−1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2010, 150:61-65.
• [23]Tumu VR, Govatati S, Guruvaiah P, Deenadayal M, Shivaji S, Bhanoori M: An interleukin-6 gene promoter polymorphism is associated with polycystic ovary syndrome in South Indian women. J Assist Reprod Genet 2013, 30:1541-1546.
• [24]Kolbus A, Walch K, Nagele F, Wenzl R, Unfried G, Huber JC: Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associated with polycystic ovary syndrome. J Reprod Immunol 2007, 73:188-193.
• [25]Yang Y, Qiao J, Tang RX, Li MZ: Genotype and haplotype determination of interleukin (IL) 1 beta (g. -511C > T and g. +3954C > T) and IL-1RN in polycystic ovary syndrome. Fertil Steril 2010, 94:384-386.
• [26]Mu Y, Liu J, Wang B, Wen Q, Wang J, Yan J, et al.: Interleukin 1 beta (IL-1beta) promoter C [−511] T polymorphism but not C [+3953] T polymorphism is associated with polycystic ovary syndrome. Endocrine 2010, 37:71-75.
• [27]Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
• [28]Yang B, Fan S, Zhi X, Li Y, Liu Y, Wang D, et al.: Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta-analysis from 114 studies with 15411 cases and 21970 controls. PLoS One 2014, 9:e87497.
• [29]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
• [30]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
• [31]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
• [32]Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
• [33]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [34]Gonzalez F, Rote NS, Minium J, Kirwan JP: Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91:1508-1512.
• [35]Repaci A, Gambineri A, Pasquali R: The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011, 335:30-41.
• [36]Gonzalez F: Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012, 77:300-305.
• [37]Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F: Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 2011, 95:1048-1058.
• [38]Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, et al.: Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003, 52:1872-1876.
• [39]Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W: Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000, 85:1334-1339.
• [40]Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, et al.: Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 2000, 49:517-520.
• [41]Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B: Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005, 90:6014-6021.
• [42]Sathyapalan T, Atkin SL: Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010, 2010:758656.
• [43]Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, et al.: The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004, 150:525-532.
• [44]Jerrard-Dunne P, Sitzer M, Risley P, Steckel DA, Buehler A, von Kegler S, et al.: Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2003, 34:402-407.
• [45]Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000, 275:18138-18144.
• [46]Carroll J, Saxena R, Welt CK: Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2012, 25:459-466.
• [47]Deligeoroglou E, Kouskouti C, Christopoulos P: The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol Endocrinol 2009, 25:603-609.